AI Article Synopsis
- Sparsentan (FILSPARI™) is an oral medication that targets two specific receptors, being developed for conditions like IgA nephropathy and FSGS.
- In February 2023, it received accelerated approval by the FDA to lower protein levels in urine for adults with severe IgA nephropathy.
- The article reviews the key milestones in the development of sparsentan that led to its first approval for treating IgA nephropathy.
Article Abstract
Sparsentan (FILSPARI™) is an oral, dual endothelin angiotensin receptor antagonist that is being developed by Travere Therapeutics for the treatment of immunoglobulin A (IgA) nephropathy and focal segmental glomerulosclerosis (FSGS). In February 2023, sparsentan received accelerated approval in the USA for reducing proteinuria in adults with primary IgA nephropathy who are at risk of rapid disease progression. This article summarizes the milestones in the development of sparsentan leading to this first approval for IgA nephropathy.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232600 | PMC |
| http://dx.doi.org/10.1007/s40265-023-01864-x | DOI Listing |
Publication Analysis
Top Keywords
iga nephropathy
12
sparsentan
4
sparsentan approval
4
approval sparsentan
4
sparsentan filspari™
4
filspari™ oral
4
oral dual
4
dual endothelin
4
endothelin angiotensin
4
angiotensin receptor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!